MYL - Mylan N.V. Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 TVIX (7.91%) DGAZ (2.48%) IWM (-0.22%) UGAZ (-2.25%) VBIV (2.63%) VXX (5.15%) LMRK (0.65%) KSS (0.46%) KR (-0.55%) KO (-1.12%) IRM (-0.47%) IMGN (5.76%) GSK (0.75%) FEYE (0.43%) FDX (-2.41%) F (0.77%) EXAS (0.56%) EPZM (-0.81%) ECA (-0.41%) DISH (-2.54%) DIS (-0.78%) COST (-0.52%) CHWY (-3.8%) CC (-1.28%) APLE (0.07%)

Volume 20% above average

MYL - Mylan N.V.

$21.00 0[0%]

15 mins delayed data

People also watch : SNY | PFE | LCI | TEVA | RDY

+Watchlist

5 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$21.00	Open	$20.61
Volume	9.18M	Market Cap	8.871B
Yield		Last Dividend

Day

52 Week

The Opioid Crisis Hits Home for Investor...	12:54 PM
Litigation against health-care companies is reaching a critical juncture. Investors need to rethink their exposure to the drug supply chain.

J&J's Prostate Cancer Drug Gets ...	09/19/19
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

Pfizer Is Spinning Off Upjohn. What’s Le...	09/19/19
J.P. Morgan’s Chris Schott told a look at what he calls New Pfizer, the biopharma business that will be left after the spinoff of the unit that makes ...

5 Undervalued Stocks to Buy	09/19/19
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market continu...

Mylan Expands Oncology Portfolio with La...	09/17/19
HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (MYL) today announced the U.S. launch of Fulvestrant Injection, 250 m...

Leaner Pfizer Positioned to Boost R&D Ou...	09/11/19
Company’s recent decisions will enable it to concentrate on building core business Continue reading...

Pfizer is a Top Drugmaker: Is it the Rig...	09/06/19
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales ...

Mapi Pharma to Present Series of Recent ...	09/04/19
Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will...

Acorda (ACOR) Down More Than 60% in 3 Mo...	09/03/19
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's d...

The 3 Worst Health Care Stocks So Far Th...	09/03/19
It hasn’t been the greatest eight months for the health-care sector, but for three companies it’s been particularly a particularly bad year.

ANALYST RATINGS

4 analyst ratings (Last 6 months)

100.00 %

Strong Buy + Buy

Price Target (PT)

Buy rating	09/12/19
SunTrust Robinson Humphrey maintains Buy rating and raises Price Target from $25.00 to $27.00

Strong Buy rating	07/30/19
and raises Price Target from $22.00 to $25.00

Strong Buy rating	06/11/19
Barclays initiates coverage with Overweight rating and announces Price Target of $26.00

Buy rating	05/08/19
Wells Fargo downgrades from Outperform to Market Perform rating and lowers Price Target from $33.00 to $22.00

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $MYL

Service Name	Trader	% Success
The profit machine	Gino Baldassano	70.00 %	Follow
Alpha Swing Trades	Jonathan	69.00 %	Follow
Options Mann	Thomas Mann	40.00 %	Follow
Symmetry Options	Symmetry Options	33.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.